Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.67 USD
+0.11 (20.00%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $0.64 -0.03 (-4.76%) 7:28 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SGMO 0.67 +0.11(20.00%)
Will SGMO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SGMO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SGMO
Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates
SGMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
Other News for SGMO
Peering Into Sangamo Therapeutics's Recent Short Interest
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results
Buy Rating Affirmed: Sangamo’s Hemophilia A Gene Therapy Poised for Success with Pfizer Partnership
Sangamo reports on Pfizer's Phase 3 results of Hemophilia A candidate